

Contact:

Loraine V. Upham

Lori@CureDM.com

(505-515-1947)

CureDM Announces New Board Members, Kevin Kaster, JD and John Amatruda, MD

Wilmington, DE – September 27, 2016 – CureDM announces the addition of two new members to the CureDM Board of Directors. **Kevin Kaster, JD** is a renowned IP attorney and business development strategist in the biotechnology industry. He has previously served in patent and licensing positions at Threshold Pharmaceuticals, Inc.; Kosan Biosciences, Inc.; Geron Corporation, Affymax Technologies, N.V., and Cetus Corp. **John Amatruda, MD** is former Senior VP and Franchise Head of Diabetes and Obesity at Merck & Co. He is board certified in Internal Medicine and Endocrinology and holds a faculty position at Yale University School of Medicine.

CEO, Loraine Upham states, “We are honored to have both Mr. Kaster and Dr. Amatruda join our Board. They are both playing very active roles and will be instrumental in our success as we progress through the clinic and our future partnering plans.” The company is actively engaged in fundraising, clinical development planning and partnering to bring forth a novel treatment approach to diabetes with their lead compound, HIP2B. HIP2B is a human derived peptide therapeutic that stimulates proteomic pathways that lead to islet neogenesis that can restore islet mass by creating new, healthy islets. Both type 1 and type 2 indications will be pursued.

About CureDM

CureDM is a biopharmaceutical company focused on the discovery and development of new therapeutics that prevent, ameliorate, or reverse diseases of metabolism. CureDM was co-founded by a molecular biologist and two endocrinologists who experienced the unmet medical need in diabetes patients on a daily basis, which provided the motivation for the discovery of HIP2B. For more information about CureDM, visit www.curedm.com.

XXXXXX